Pharmacologic limits of the protective effect of polyaspartic acid on experimental gentamicin nephrotoxicity

Antimicrob Agents Chemother. 1993 Feb;37(2):347-8. doi: 10.1128/AAC.37.2.347.

Abstract

Polyaspartic acid (PAA) ameliorates experimental gentamicin nephrotoxicity despite marked accumulation of gentamicin in the renal cortex. The experiments described here probe the extent of PAA's nephroprotective action when increasing doses of gentamicin, in excess of an established nephrotoxic dose (40 mg/kg of body weight per day), are administered. After 10 days, virtually complete nephroprotection was conferred by PAA coadministered to animals receiving three times the nephrotoxic dose (120 mg/kg/day) of gentamicin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Creatinine / blood
  • Gentamicins / antagonists & inhibitors*
  • Gentamicins / metabolism
  • Gentamicins / toxicity
  • Injections, Subcutaneous
  • Kidney / pathology
  • Kidney Cortex / metabolism
  • Kidney Diseases / chemically induced
  • Kidney Diseases / pathology
  • Kidney Diseases / prevention & control*
  • Male
  • Peptides / administration & dosage
  • Peptides / therapeutic use*
  • Rats
  • Rats, Inbred F344

Substances

  • Gentamicins
  • Peptides
  • polyaspartate
  • Creatinine